"Outcomes of anticoagulant (AC) or antiplatelet (AP) use in patients (pts) with chronic lymphocytic leukemia (CLL) or indolent non-Hodgkin’s lymphoma (iNHL) in idelalisib (IDELA) trials." by Jacqueline Claudia Barrientos

Selected Works of John M. Pagel, MD, PhD

Article

Outcomes of anticoagulant (AC) or antiplatelet (AP) use in patients (pts) with chronic lymphocytic leukemia (CLL) or indolent non-Hodgkin’s lymphoma (iNHL) in idelalisib (IDELA) trials.

Journal of Clinical Oncology (2017)

Jacqueline Claudia Barrientos, Hofstra University
Paolo Ghia, Vita-Salute San Raffaele University
John Pagel, Cancer Institute
Gilles A. Salles, Claude Bernard University Lyon 1
Jeff Porter Sharman, Cancer Institute
Stephan Stilgenbauer, University of Ulm
Oksana Gurtovaya
Yeonhee Kim
Betsy Philip
Andrew David Zelenetz, Memorial Sloan Kettering Cancer Center

Link

Disciplines

Publication Date

January 31, 2017

Citation Information

Jacqueline Claudia Barrientos, Paolo Ghia, John Pagel, Gilles A. Salles, et al.. "Outcomes of anticoagulant (AC) or antiplatelet (AP) use in patients (pts) with chronic lymphocytic leukemia (CLL) or indolent non-Hodgkin’s lymphoma (iNHL) in idelalisib (IDELA) trials." Journal of Clinical Oncology (2017)
Available at: http://works.bepress.com/john-pagel/19/